Your liver is constantly converting cholesterol into bile acids — the detergent-like molecules that emulsify dietary fat and exit the body via the gut. The enzyme that sets the pace for this entire process is cholesterol 7α-hydroxylase¹¹ cholesterol 7α-hydroxylase
CYP7A1 catalyzes the first and rate-limiting step of the classic bile acid synthesis pathway, converting cholesterol to 7α-hydroxycholesterol, encoded by the CYP7A1 gene. The faster this enzyme works, the more cholesterol gets converted to bile acids and cleared, and the lower your LDL tends to be. Variants upstream of CYP7A1 — including rs1125226 — help define haplotypes that collectively tune how much bile acid your liver produces.

The Mechanism

CYP7A1 sits in hepatocyte endoplasmic reticulum membranes and governs the neutral (classic) bile acid pathway²² neutral (classic) bile acid pathway
The classic pathway accounts for ~75% of all bile acid production in humans; the alternative acidic pathway handles the remainder. Its expression is regulated by a network of nuclear receptors: LXRα activates CYP7A1 transcription in response to excess hepatic cholesterol, while FXR (activated by returning bile acids from the gut) represses it as a feedback brake. rs1125226 sits approximately 6.8 kb upstream of the CYP7A1 transcription start site — within the extended promoter/regulatory region — and is a haplotype-tagging SNP for this gene. It was characterised as part of a systematic mapping of CYP7A1's linkage disequilibrium blocks³³ linkage disequilibrium blocks
regions of the genome inherited together more often than chance alone across five population groups.

The rs1125226 A allele co-segregates with specific CYP7A1 promoter haplotypes, of which the well-studied rs3808607 variant is the primary functional site. In hepatocyte assays, the rs3808607 G allele (which travels with certain rs1125226 haplotypes) drives higher CYP7A1 mRNA expression⁴⁴ higher CYP7A1 mRNA expression
Inamine et al. 2013: the G-allele promoter induced significantly higher CYP7A1 expression under both normal and cholestatic conditions than the T allele. The combined two-SNP regulatory model spanning promoter and enhancer spans more than two orders of magnitude in hepatic CYP7A1 expression⁵⁵ two orders of magnitude in hepatic CYP7A1 expression
Wang et al. 2018: only the two-SNP model, not either SNP alone, significantly associated with LDL levels, CAD risk, statin response, and T2D.

The Evidence

A 2023 meta-analysis by Lim et al.⁶⁶ Lim et al.
Lim MYC et al. A meta-analysis of the pooled impact of CYP7A1 single nucleotide polymorphisms on serum lipid responses to statins. Front Genet, 2023 pooled statin-response data and found that CYP7A1 variant carriers had significantly smaller reductions in total cholesterol (WMD −0.17 mmol/L, 95% CI −0.29 to −0.06) and LDL (WMD −0.16 mmol/L, 95% CI −0.26 to −0.05) compared to non-carriers.

Dietary studies add a complementary picture. Wang et al. 2017⁷⁷ Wang et al. 2017
Wang Y et al. Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism. Br J Nutr, 2017 showed that high-molecular-weight barley β-glucan increased bile acid synthesis in all participants, but the effect was "more pronounced" in homozygous G carriers at rs3808607 — the individuals whose CYP7A1 promoter appears most responsive. This genotype-by-diet interaction suggests that dietary cholesterol-lowering strategies targeting bile acid excretion may be especially effective for people whose CYP7A1 is already tuned high.

The earlier Hubacek & Bobkova review⁸⁸ Hubacek & Bobkova review
Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther, 2006 summarised the opposing direction of effect: −204CC homozygotes (at rs3808607) showed the greatest cholesterol reduction from dietary changes, while the −204AA homozygotes responded slightly better to statin therapy. This divergence likely reflects the enzyme's feedback relationship with statins — statins upregulate CYP7A1 as a compensatory mechanism, and individuals with higher baseline CYP7A1 activity may have a ceiling effect.

Direct evidence for rs1125226 alone is limited. The Fu et al. 2011 study⁹⁹ Fu et al. 2011 study
Fu L et al. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res, 2011 found no significant independent effect of rs1125226 genotype on hypertension susceptibility, though haplotypes combining rs3808607 and rs1125226 alleles showed significant differences. rs1125226 is best interpreted as a haplotype marker that defines which CYP7A1 regulatory environment you carry, rather than as an independent functional variant.

Practical Actions

For A allele carriers whose haplotype co-occurs with lower CYP7A1 activity signatures, a practical strategy is to emphasise dietary routes that maximise bile acid excretion. Soluble fibre from oats, barley (β-glucan), psyllium, and legumes binds bile acids in the gut and forces the liver to convert more cholesterol to replace them — effectively using diet to compensate for a genetically slower enzymatic throttle. LDL response to statin therapy should be monitored, as meta-analytic data suggest carriers may achieve somewhat smaller LDL reductions at standard doses.

For CC homozygotes, the complementary picture holds: dietary interventions targeting bile acid excretion are likely to be especially responsive, while statin response may be modestly blunted relative to the population average.

Interactions

rs1125226 is a haplotype partner to rs3808607, the CYP7A1 A-204C promoter variant. Their combined haplotype structure is the primary lens through which CYP7A1 regulatory variation should be interpreted — no single SNP in this region tells the whole story. Additionally, CYP7A1 operates at the top of the bile acid synthesis cascade; variants in downstream genes (CYP8B1, BSEP/ABCB11, FXR/NR1H4) and in the cholesterol clearance pathway (APOE rs429358, LDLR) can modify the net effect of CYP7A1 haplotype variation on plasma LDL.

The FCRL3¹¹ FCRL3
Fc receptor-like 3; expressed at high levels on B cells and regulatory T cells, where it modulates activation thresholds and autoantibody production through immunoreceptor tyrosine-based inhibitory and activation motifs (ITIMs and ITAMs) gene sits on chromosome 1q23, a region densely populated with immune receptor genes. rs11264799 lies approximately 59 bp from the well-studied rs7528684 promoter variant, placing it squarely in the upstream regulatory landscape of FCRL3. The variant itself does not change the FCRL3 protein — it is classified as an upstream transcript variant — but it exerts a measurable influence on how much FCRL3 is produced in immune cells.

FCRL3 is on the minus strand of chromosome 1; the alleles reported in genome files (C and T) are plus-strand notation. The C allele is the GRCh38 reference and the more common allele globally (~73%); the T allele is the minor variant (~27%) that carries the eQTL signal.

The Mechanism

rs11264799 has been identified as a strong expression quantitative trait locus (eQTL)²² strong expression quantitative trait locus (eQTL)
eQTLs are genetic variants that influence the amount of RNA or protein produced by a nearby gene; they act as natural experiments showing how subtle regulatory changes alter gene dosage in human tissues for FCRL3. In B cells and regulatory T cells, higher FCRL3 expression alters the balance between activation and inhibition: more surface FCRL3 can either amplify or dampen B cell receptor signals depending on the cellular context. The T allele's eQTL effect on FCRL3 expression in lymphoid tissue explains why it has been repeatedly captured in genetic studies of conditions where B cell tolerance is central — IgA nephropathy, autoimmune thyroid disease, and inflammatory arthritis — even though the individual SNP associations are smaller and less consistent than those seen for the closely linked rs7528684 promoter variant.

The T allele is in linkage disequilibrium with rs6427389, a variant that reached genome-wide significance (OR=1.132, P=8.18×10⁻⁹) in a large IgAN GWAS meta-analysis; the authors noted that rs11264799 was the likely functional mediator through its FCRL3 eQTL activity.

The Evidence

The clearest evidence for rs11264799 comes from IgA nephropathy, a condition in which autoantibodies against galactose-deficient IgA1 drive mesangial immune complex deposition and progressive kidney disease. A large Chinese case-control study of 1,750 IgAN patients and 2,500 controls³³ large Chinese case-control study of 1,750 IgAN patients and 2,500 controls
Zhong Z, Feng S, Shi D et al. Association of FCRL3 Gene Polymorphisms with IgA Nephropathy in a Chinese Han Population. DNA Cell Biol 39:154–162, 2020 found rs11264799 significantly associated with IgAN susceptibility after Bonferroni correction, with the T allele linked to altered FCRL3 expression. A subsequent genome-wide meta-analysis across Chinese and European IgAN cohorts⁴⁴ genome-wide meta-analysis across Chinese and European IgAN cohorts
Li M et al. Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci. J Am Soc Nephrol 31:2045–2057, 2020 confirmed the 1q23.1 FCRL3 locus at genome-wide significance, identifying rs11264799 as the key eQTL variant underlying the association signal.

In the broader autoimmune context, a meta-analysis of 34 case-control studies⁵⁵ meta-analysis of 34 case-control studies
Yang Y, Su X, Zhang K, Zhou R. Autoimmunity 46:547–558, 2013 found rs11264799 significantly associated with autoimmune diseases in mixed ethnic subgroups, though associations in individual European or Asian populations were not consistently replicated across diseases. Heterogeneity between studies — different LD structures, disease definitions, and population ancestries — explains why single-study results for this variant are frequently negative even when the eQTL signal at the locus is robust.

For rheumatoid arthritis, multiple sclerosis, and SLE individually, rs11264799 has not shown independent replication in European cohorts; the bulk of disease association evidence for FCRL3 in these conditions is carried by the closely linked rs7528684. The evidence base for rs11264799 specifically is therefore classified as emerging.

Practical Actions

The T allele at rs11264799 acts primarily through altered FCRL3 expression, placing this variant in the same functional context as rs7528684: conditions where B cell hyperactivity and impaired immune tolerance are central. The most directly supported disease link is IgA nephropathy; broader autoimmune connections remain plausible given the eQTL mechanism but are not independently confirmed for this variant.

For TT carriers, the most actionable step is awareness of early IgAN symptoms — particularly recurrent visible haematuria (blood in urine) following upper respiratory infections, which is the hallmark presentation — and periodic urinalysis to detect subclinical proteinuria or microhaematuria before kidney function is affected.

Interactions

rs11264799 is 59 bp from rs7528684 in the FCRL3 upstream region; both variants influence FCRL3 expression and are likely to be in partial linkage disequilibrium. The rs7528684 G allele has the stronger and better-replicated autoimmune association (RA, Graves' disease, Hashimoto's thyroiditis via NF-κB binding), while rs11264799 contributes an additional eQTL layer that may operate semi-independently. Carriers of risk alleles at both loci may have amplified FCRL3 dysregulation compared to carriers of either alone, though direct compound heterozygosity data are not yet published.

Interleukin-1 beta (IL-1β) is one of the most potent pro-inflammatory cytokines in the human immune system¹¹ one of the most potent pro-inflammatory cytokines in the human immune system
IL-1β activates NF-κB signaling, drives fever, induces acute phase proteins, promotes neutrophil recruitment, and directly stimulates bone resorption — all fundamental to both protective immunity and inflammatory disease. The IL1B gene encodes this cytokine on chromosome 2, and the rs1143634 variant at exon 5 position +3954 presents an unusual biological puzzle: a synonymous mutation — one that preserves the amino acid sequence — that nonetheless changes how much IL-1β protein the body produces²² a synonymous mutation — one that preserves the amino acid sequence — that nonetheless changes how much IL-1β protein the body produces
The F105F substitution (Phe→Phe) is silent at the protein level but functionally loud at the secretion level.

The Mechanism

The +3954C>T variant (rs1143634) is located in exon 5 of IL1B, in the region encoding the mature IL-1β protein's domain critical for receptor binding. Despite causing no amino acid change at position 105 (phenylalanine is retained regardless of C or T), carriers of the T allele produce substantially more IL-1β protein after immune stimulation³³ carriers of the T allele produce substantially more IL-1β protein after immune stimulation
In a study of aseptic implant loosening, T allele carriers had plasma IL-1β levels of 11.79 pg/mL versus 2.11 pg/mL in CC homozygotes after stimulation — a 5.6-fold difference.

The mechanism by which a synonymous codon change alters protein secretion likely operates at the post-transcriptional level. Synonymous variants can alter mRNA secondary structure, codon usage optimization, or regulatory element binding within the coding sequence⁴⁴ alter mRNA secondary structure, codon usage optimization, or regulatory element binding within the coding sequence
These effects can influence mRNA stability, translation efficiency, or protein folding — and for IL-1β, which requires caspase-1 cleavage for secretion, subtle conformational changes in the precursor protein could plausibly accelerate or facilitate the secretion process. In vitro studies show that the T allele leads to measurably higher IL-1β release from lipopolysaccharide-stimulated immune cells compared to the C allele.

This variant is distinct from the better-known promoter variants in IL1B: rs16944 (-511C>T) and rs1143627 (-31T>C)⁵⁵ rs16944 (-511C>T) and rs1143627 (-31T>C)
These two promoter variants regulate IL-1β transcription; rs1143634 instead appears to affect post-translational secretion or processing, providing an independent second tier of IL-1β output control. A person who carries high-producing alleles at multiple IL1B loci may have compounded elevation of IL-1β output.

The Evidence

The strongest and most consistent evidence links rs1143634 to periodontal disease. A meta-analysis of 54 case-control studies encompassing 9,376 participants⁶⁶ meta-analysis of 54 case-control studies encompassing 9,376 participants
Association between the rs1143634 polymorphism in interleukin-1B and chronic periodontitis. Journal of Periodontal Research, 2018 found the T allele significantly associated with chronic periodontitis risk (OR 1.35, 95% CI 1.24–1.48; p < 0.00001). Stratified analyses confirmed the association in Caucasian, Asian, and mixed populations, though not in African ancestry cohorts.

The aseptic joint loosening study⁷⁷ aseptic joint loosening study
IL-1β gene (+3954C/T) and NOS2 polymorphisms associate with early aseptic loosening of arthroplasties. Scientific Reports, 2022 provided some of the most compelling functional evidence: patients with the TT genotype showed a 3.7-fold higher hazard of requiring revision surgery within 5 years (HR 3.70, 95% CI 1.27–10.75), with the elevated IL-1β levels directly driving peri-implant bone resorption. This study confirmed the secretion phenotype rather than just disease association.

For cancer risk, an updated meta-analysis of 44 studies (18,645 cancer patients, 22,882 controls)⁸⁸ updated meta-analysis of 44 studies (18,645 cancer patients, 22,882 controls)
Role of IL-1β rs1143634 (+3954C>T) polymorphism in cancer risk. International Journal of General Medicine, 2021 found the T allele associated with modestly elevated overall cancer risk (allelic model OR 1.08). Gastric cancer, breast cancer, and multiple myeloma showed the most consistent signals in subgroup analyses.

In inflammatory bowel disease, IL1B gene polymorphisms including the exon 5 variant were shown to influence the course and severity of IBD in a study of 96 UC and 98 Crohn's patients⁹⁹ IL1B gene polymorphisms including the exon 5 variant were shown to influence the course and severity of IBD in a study of 96 UC and 98 Crohn's patients
IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Gut, 2000, establishing a role for this variant in gastrointestinal inflammatory disease progression rather than susceptibility alone.

A notable negative finding: the T allele is not associated with aggressive periodontitis (OR 0.99, 95% CI 0.79–1.23 in a 25-study meta-analysis) — the association is specific to chronic periodontitis. This distinction matters clinically: aggressive and chronic periodontitis have different etiologies and risk profiles, and the IL-1β elevation associated with this variant appears to drive the sustained chronic inflammatory pattern rather than acute-onset aggressive disease.

Practical Actions

Elevated IL-1β production from this variant is not inevitably harmful — it is a quantitative trait that becomes clinically relevant under specific conditions. The most actionable implications:

Dental health: Carriers of one or two T alleles have meaningfully elevated periodontal risk. The T allele is particularly dangerous in combination with smoking, where the risk amplifies substantially. The variant provides a genetic basis for prioritizing periodontal care beyond standard recommendations.

Inflammatory conditions: Elevated baseline IL-1β production may accelerate inflammation-driven tissue damage in contexts ranging from joint prostheses to gastrointestinal mucosa. Conditions where IL-1β is a known mediator — including gout, IBD flares, and peri-implant inflammation — may be more severe in T allele carriers.

Cancer context: The modest cancer risk elevation (OR ~1.08) is not sufficient to change standard screening protocols, but it reinforces the importance of anti-inflammatory strategies and standard cancer screening adherence.

Interactions

rs1143634 is part of the IL1B locus on chromosome 2q14.1, which also encodes IL1A, and is co-located with the IL1RN gene encoding the IL-1 receptor antagonist. The promoter variants rs16944 (−511) and rs1143627 (−31) regulate IL-1β transcription via different mechanisms from rs1143634. A person carrying risk alleles at both the promoter level (rs16944) and the exon 5 level (rs1143634) may have compounded IL-1β output — both more transcript and more efficient secretion of the protein.

Interaction with IL1RN rs419598 (the IL-1 receptor antagonist gene) is biologically important: IL-1Ra counterbalances IL-1β by competing for the IL-1 receptor without signaling. Carrying the rs1143634 T allele (high IL-1β) alongside low-producing IL-1Ra variants may amplify net IL-1 signaling substantially.

The composite IL-1 genotype combining IL1A rs1800587 and IL1B rs1143634 was shown to have a 2.84-fold risk of chronic periodontitis in smokers (OR 4.43 in male smokers, OR 6.00 in female smokers)¹⁰¹⁰ a 2.84-fold risk of chronic periodontitis in smokers (OR 4.43 in male smokers, OR 6.00 in female smokers)
Interaction of IL1B and IL1RN polymorphisms, smoking, gender and ethnicity with aggressive and chronic periodontitis susceptibility. J Clin Periodontol, 2016, illustrating that single-variant effects are substantially potentiated in this combined context.

Endometriosis affects an estimated 10% of reproductive-age women and remains one of the most under-diagnosed causes of chronic pelvic pain and infertility. The condition is estrogen-dependent: ectopic lesions generate their own local estrogen supply through elevated aromatase activity, and this autocrine estrogen loop drives lesion proliferation and immune evasion. GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output¹¹ GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output
Chadchan et al. Nature Communications, 2024.

rs11674184 is an intronic variant in GREB1 at chromosome 2p25.1 that was identified as a statistically independent endometriosis risk signal in the landmark 2023 Rahmioglu Nature Genetics multi-ancestry GWAS meta-analysis. Critically, it is not simply a proxy for the previously described rs13394619 GREB1 variant already in the GeneOps database: the two variants have r²=0.65 in European populations — moderate linkage disequilibrium, not the r²>0.8 threshold that would indicate redundancy. They tag different aspects of the GREB1 regulatory landscape.

The GRCh38 reference allele (T) is the risk allele here, with the less common G allele conferring protection. This is the reverse of the intuitive direction — the T allele at rs11674184 is common (~63% globally) and constitutes the risk-conferring genotype.

The Mechanism

GREB1 operates as a context-dependent steroid hormone cofactor. In normal endometrium during the secretory phase, GREB1 binds the progesterone receptor and promotes downstream decidualization targets including WNT4 and FOXO1A²² In normal endometrium during the secretory phase, GREB1 binds the progesterone receptor and promotes downstream decidualization targets including WNT4 and FOXO1A
Chadchan et al. 2024. In endometriotic lesions, where estrogen dominates, GREB1 switches roles to act as an estrogen receptor cofactor — amplifying estrogen-driven gene expression and ectopic cell proliferation. GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women³³ GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women
Pellegrini et al. Fertility and Sterility, 2012. Mouse knockout models with GREB1 deletion show substantially reduced ectopic lesion volume and mass.

The intronic rs11674184 variant lies within c.901+577 of the GREB1 transcript. Its modest CADD score (~7.7) and low evolutionary constraint (GERP −0.61) suggest limited direct functional impact on the protein, consistent with a regulatory tag SNP. Fine-mapping of the GREB1 locus by Fung et al. 2015 (Human Reproduction)⁴⁴ Fung et al. 2015 (Human Reproduction)
Fung et al. Fine mapping of GREB1 in endometriosis, 2015 identified multiple intronic variants at this locus with independent association signals, suggesting the region contains at least two distinct regulatory elements influencing GREB1 expression or splicing in endometrial tissue.

The Evidence

Rahmioglu et al. 2023 (Nature Genetics)⁵⁵ Rahmioglu et al. 2023 (Nature Genetics) conducted the largest endometriosis GWAS to date, incorporating data from 23andMe and major biobanks across European and East Asian populations. rs11674184 reached genome-wide significance for all endometriosis (risk allele T: OR=1.13, 95% CI 1.10–1.15, P=3×10⁻¹⁷) and showed a stronger association for confirmed Stage III/IV disease (OR=1.16, P=6×10⁻⁹), consistent with the pattern seen for the nearby rs13394619 where the GREB1 locus effect is enriched in moderate-to-severe disease.

A small Greek case-control study (166 cases, 168 controls) by Matalliotaki et al. 2019 (Molecular Medicine Reports)⁶⁶ Matalliotaki et al. 2019 (Molecular Medicine Reports)
Matalliotaki et al. 2019 found no association for rs11674184, which the authors acknowledged was "one of the most consistently associated SNPs with endometriosis in European ancestry populations." The non-significant result in this study is consistent with insufficient statistical power rather than a true null: the effect size (OR≈1.13) and a sample of 166 cases would require approximately 2,000+ cases to reach genome-wide significance. The Rahmioglu 2023 finding with many thousands of cases is authoritative on this point.

The T allele frequency shows marked ancestry stratification: approximately 0.62 in Europeans, 0.57 in East Asians, but only approximately 0.24 in African populations — meaning GG protective homozygotes are far more common in women of African ancestry (~58%) than in Europeans (~14%).

Practical Implications

Carrying T alleles at rs11674184 raises endometriosis susceptibility, with OR≈1.13 per allele across the full endometriosis phenotype and OR≈1.16 for Stage III/IV. As with all common GWAS variants, these are population-level probability shifts rather than deterministic predictions. The key actionable implication is recognizing and acting on symptoms promptly. Endometriosis diagnostic delay averages 7–9 years across many healthcare systems, driven by normalization of menstrual pain. Women carrying the TT genotype — with the highest common genetic load at this locus — have the strongest motivation to pursue early specialist evaluation rather than accepting pain as normal.

For TT carriers in whom fertility is a consideration, the particular enrichment of this variant's effect at Stage III/IV disease supports proactive ovarian reserve assessment: moderate-to-severe endometriosis, especially ovarian endometriomas, is the mechanism through which endometriosis most directly impairs fertility.

Interactions

rs13394619 (GREB1): The other replicated intronic GREB1 variant in the GeneOps database. The two variants have r²=0.65 in European populations — they share roughly 65% of their variance but are not redundant. Women carrying risk alleles at both rs11674184 (TT or GT) and rs13394619 (GG or AG) may represent a subgroup with elevated cumulative GREB1-pathway genetic load. No formal published study has tested the joint effect of both variants in the same sample; pending such analysis, the individual effects should be considered as partially overlapping but not identical signals.

For supervisor compound action proposal: women carrying the T risk allele at rs11674184 (TT or GT) AND the G risk allele at rs13394619 (GG or AG) carry both GREB1 locus signals simultaneously. The combined recommendation would be: lower threshold for specialist gynecological referral, earlier baseline ovarian reserve testing (AMH + antral follicle count), and proactive fertility counseling. Evidence level: moderate (both independently established at the GREB1 locus; combined effect inferred from consistent additive direction but LD of r²=0.65 means they partially overlap; formal joint analysis not yet published).

rs12700667 (7p15.2, HOXA locus): The other major replicated endometriosis GWAS locus, operating through regulation of HOXA10/HOXA11 — distinct biological pathway from GREB1. Both loci show independent additive effects on endometriosis risk in GWAS meta-analyses, both show stronger signals for Stage III/IV disease, and women carrying risk alleles at both may represent the highest-risk common-variant group identifiable today.

Every cell in your body continuously breaks down and recycles old molecular scaffolding — including glycosaminoglycans¹¹ glycosaminoglycans
Long sugar-chain molecules embedded in cartilage, bone, and connective tissue that give these tissues their structural properties, such as keratan sulfate and chondroitin-6-sulfate. This recycling happens inside lysosomes, tiny cellular recycling compartments, and requires a precise sequence of enzymes. The GALNS gene encodes N-acetylgalactosamine-6-sulfate sulfatase²² N-acetylgalactosamine-6-sulfate sulfatase
EC 3.1.6.4 — an enzyme that removes sulfate groups from the keratan sulfate and chondroitin-6-sulfate sugar chains as they are broken down step by step, one of those critical enzymes. When GALNS is deficient, these glycosaminoglycans accumulate in lysosomes, distorting cells and progressively destroying cartilage and bone. The result is Mucopolysaccharidosis Type IVA (MPS IVA), also known as Morquio syndrome A.

The rs118204437 A allele (c.1156C>T on the coding strand; G>A on the plus genomic strand) changes arginine to cysteine at protein position 386. This is the single most frequently reported GALNS pathogenic variant worldwide, found in approximately 5% of all mutant GALNS alleles in the global literature — and in up to 32.5% of alleles from Latin American cohorts, consistent with a founder effect³³ founder effect
A founder effect occurs when a small ancestral population carrying a mutation gives rise to a larger population, concentrating that mutation at a higher frequency than in the general global population.

The Mechanism

The arginine at position 386 sits in the catalytic core of the GALNS enzyme⁴⁴ catalytic core of the GALNS enzyme
Structural analyses show Arg386 is a buried residue that stabilizes the substrate-binding pocket; its replacement by cysteine disrupts this architecture through changes in charge, polarity, and disulfide-bond potential. Biochemical studies confirm that the Arg386Cys substitution produces no detectable residual enzyme activity — placing it firmly in the severe phenotype category. Patients homozygous for R386C, or compound heterozygous for R386C paired with another null allele, typically present with the full severe form of MPS IVA: progressive skeletal dysplasia, short stature, joint hypermobility, corneal clouding, and cardiorespiratory involvement. A rat model was constructed by engineering the equivalent substitution (Arg388Cys) into the rodent GALNS gene, and it faithfully recapitulates the human skeletal and non-skeletal disease phenotype.

Because GALNS is encoded on the minus strand of chromosome 16, the coding-strand notation (c.1156C>T) and the plus-strand genomic notation (G>A at chr16:88,824,853) appear as complements of each other. Genome files from WGS or consumer genotyping report the plus-strand allele (G reference, A alternate).

The Evidence

Morrone et al. (2014)⁵⁵ Morrone et al. (2014)
Morrone A et al. Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database. Hum Mutat, 2014 curated 1,091 GALNS alleles from the global literature and identified Arg386Cys as the single most common, accounting for 5% of all alleles. It was distributed across 30 countries, with the highest concentration in Spain (25% of Spanish patient alleles), Argentina (11%), and China (9%). Its worldwide distribution and high relative frequency point to both ancient founder events and recurrent de-novo mutation at a CpG-adjacent site.

Tomatsu et al. (2005)⁶⁶ Tomatsu et al. (2005)
Tomatsu S et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat, 2005 documented the broader GALNS mutation landscape in 148 unique alleles, confirming that Arg386Cys is one of the three mutations exceeding 5% prevalence, and that CpG-dinucleotide transitions (which include this mutation's mechanism) account for 26% of all GALNS pathogenic changes.

A large genotype-phenotype study by Yi et al. (2022)⁷⁷ Yi et al. (2022)
Yi Y et al. Investigation of GALNS variants and genotype-phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA. J Inherit Metab Dis, 2022 analyzing 108 MPS IVA patients established that buried-residue missense variants (the class to which R386C belongs) drive severe phenotype in 92% of cases, providing a structural rationale for genotype-based prognosis.

ClinVar (Variation ID 700) lists 14 submissions from major genetics laboratories on four continents — Labcorp Genetics, Baylor Genetics, University of Padova, and Shriners Hospital — all independently classifying the variant as Pathogenic or Likely Pathogenic (2-star review status, no conflicts, last updated January 2026).

Practical Actions

MPS IVA has no cure, but the disease can be actively managed. The FDA approved elosulfase alfa (Vimizim), a recombinant form of GALNS enzyme, in February 2014. Administered weekly at 2 mg/kg IV, it reduces urinary keratan sulfate (a disease biomarker) by ~53% sustained over 5+ years of real-world follow-up, and a phase III randomized trial demonstrated a statistically significant improvement in six-minute walk test distance (+22.5 m, 95% CI 4–41 m) versus placebo. Early initiation before irreversible skeletal damage maximizes benefit.

Asymptomatic heterozygous carriers (GA genotype) require no personal clinical intervention, but genetic counseling is recommended before family planning. Each child of two confirmed carriers has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected. Prenatal and preimplantation genetic testing are available once pathogenic variants are confirmed in both parents.

Interactions

MPS IVA is a monogenic recessive disease: the clinical outcome is determined primarily by whether a person carries two loss-of-function GALNS alleles (compound heterozygous or homozygous). Arg386Cys paired with a second null allele (frameshift, nonsense, or splice site) typically results in the same severe phenotype as homozygous R386C, because both copies of GALNS are non-functional. Compound heterozygosity with attenuated missense alleles (those retaining 1–13% residual activity) can produce intermediate or mild phenotypes. Assessment of the second allele is therefore critical for prognosis in affected individuals.

Your body cannot make zinc — every atom of it must come through your intestine. ZIP4¹¹ ZIP4
Zinc/Iron-regulated transporter-like Protein 4, encoded by SLC39A4, is the dominant apical zinc importer in duodenal and jejunal enterocytes, the protein encoded by SLC39A4, sits at the brush border of the small intestine and acts as the primary gateway for dietary zinc absorption. When both copies of SLC39A4 carry loss-of-function variants, zinc simply cannot get in — and the resulting deficiency is profound and life-threatening without treatment.

This SNP, rs121434290, captures a missense change at codon 106 that replaces asparagine with lysine (p.Asn106Lys). The variant was first reported in a compound heterozygous French family²² compound heterozygous French family
Küry S et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet, 2002, where one chromosome carried this missense change and the other carried an approximately 2-kb upstream deletion that abolished gene expression. The compound heterozygosity was sufficient to cause full acrodermatitis enteropathica (AE)³³ acrodermatitis enteropathica (AE)
A rare autosomal recessive disorder of zinc malabsorption presenting with the classic triad of periorificial and acral dermatitis, chronic diarrhea, and alopecia; incidence ~1 in 500,000 newborns globally.

The Mechanism

ZIP4 is a transmembrane zinc transporter with eight predicted membrane-spanning domains and an extracellular amino-terminal domain that is essential for function. Asparagine 106 lies within this extracellular domain⁴⁴ extracellular domain
The N-terminal ectodomain of ZIP4 folds into a petal-like structure that binds zinc and facilitates its delivery to the transmembrane channel. Under zinc-replete conditions, this domain is proteolytically shed as a regulatory response; under zinc-deficient conditions, the full-length protein is stabilized to maximize uptake and contributes to the folded structure required for zinc capture and channel opening. The Asn106Lys substitution disrupts normal ectodomain function — a 2009 molecular study⁵⁵ 2009 molecular study
Mao X et al. Novel proteolytic processing of the ectodomain of the zinc transporter ZIP4 (SLC39A4) during zinc deficiency is inhibited by acrodermatitis enteropathica mutations. J Biol Chem, 2009 demonstrated that several AE-causing missense mutations, including variants at conserved positions in this domain, block the regulated proteolytic cleavage that normally fine-tunes ZIP4 surface expression in response to dietary zinc availability.

When both ZIP4 alleles are non-functional, zinc absorption in the duodenum and proximal jejunum falls to near zero. Zinc is required as a cofactor for over 300 enzymes and 2,000 transcription factors; its loss disrupts epithelial integrity, T-cell function, wound healing, and cell division. Serum zinc drops below 7 μmol/L (normal 9.8-16.8 μmol/L), and alkaline phosphatase — a zinc-dependent enzyme — is a reliable early marker of deficiency.

The Evidence

SLC39A4 was identified simultaneously by two groups in 2002: Küry et al. in Nature Genetics and Wang et al. in the American Journal of Human Genetics, reporting mutations in eight and five AE families respectively. Since then, a 2009 systematic update⁶⁶ 2009 systematic update
Schmitt S et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat, 2009 catalogued over 31 distinct mutations spread across the entire gene — missense, nonsense, frameshift, splice-site, and large deletions — with no clear genotype-phenotype correlation between specific mutation type and clinical severity. The N106K missense variant (this SNP) is one of the founding pathogenic variants described in that initial discovery.

Carrier parents of AE children are uniformly asymptomatic for zinc deficiency under normal dietary conditions. Mouse studies suggest heterozygous Zip4 animals are approximately 10 times more sensitive to zinc deficiency during pregnancy than wild-type littermates (Dufner-Beattie et al. Human Mol Genet, 2007⁷⁷ Dufner-Beattie et al. Human Mol Genet, 2007), but this has not been translated into clinically actionable guidance for human carriers at normal dietary zinc intake.

Treatment with oral zinc supplementation (3 mg/kg/day elemental zinc, typically as zinc sulfate) is dramatically effective in homozygous patients, with clinical improvement within days and full symptom resolution within weeks. StatPearls AE review⁸⁸ StatPearls AE review cites a 100% response rate with adequate zinc replacement; without treatment, the condition is fatal within early childhood.

Practical Actions

For carriers (GT genotype): carrier status has implications for family planning and genetic screening of at-risk relatives, but does not ordinarily require dietary zinc adjustment. Serum zinc monitoring is warranted during pregnancy due to the heightened zinc demands of fetal development.

For homozygous individuals (TT genotype): lifelong oral zinc supplementation is mandatory. Monitoring must include not only plasma zinc but also serum copper — chronic high-dose zinc competitively inhibits copper absorption through shared transport proteins, and copper deficiency can develop silently. Alkaline phosphatase activity is a useful surrogate marker reflecting the zinc status of both bone and intestinal tissue.

Interactions

Because AE is autosomal recessive, a second loss-of-function SLC39A4 variant must be present on the other chromosome for full disease expression. Clinical sequencing of AE patients typically reveals compound heterozygosity for two different mutations — as in the original family where this N106K variant paired with a promoter deletion. This means a person carrying this variant and a different SLC39A4 pathogenic variant in trans would be clinically affected even though neither individual variant is homozygous. Comprehensive SLC39A4 gene sequencing (not just SNP genotyping) is needed for complete clinical evaluation.

The PTPN22 gene is widely known for its R620W variant (rs2476601), one of the strongest non-HLA autoimmune risk factors. But R620W is not the only functional player in this locus. Deep sequencing and haplotype studies have revealed that multiple independent signals exist within PTPN22¹¹ multiple independent signals exist within PTPN22
Haplotype analysis of 37 SNPs identified two additional PTPN22 variants associated with RA independent of R620W, each potentially influencing immune regulation through different mechanisms. rs1217414 is one such secondary variant — an intronic SNP that has been associated with psoriasis, ankylosing spondylitis, and autoimmune conditions in populations where R620W is effectively absent.

The Mechanism

rs1217414 sits within an intron of PTPN22 at GRCh38 chromosome 1 position 113,870,044. PTPN22 is transcribed on the minus strand, so genome files report the plus-strand alleles (G/A), while many publications report the complementary coding-strand alleles (C/T). The G allele (plus strand) corresponds to C on the coding strand; the A allele (plus strand) corresponds to T. As an intronic variant, rs1217414 has no direct effect on protein sequence. Its functional impact is most likely regulatory — intronic variants can affect splicing efficiency, create or destroy binding sites for splicing factors, or alter local chromatin accessibility²² regulatory — intronic variants can affect splicing efficiency, create or destroy binding sites for splicing factors, or alter local chromatin accessibility
Intronic variants near exon-intron boundaries or within regulatory elements can modulate mRNA splicing and transcription factor binding, altering PTPN22 expression level or isoform ratios in immune cells.

The low LD between rs1217414 and R620W³³ low LD between rs1217414 and R620W
The psoriasis study found rs2476601 showed no association when rs1217414 was significantly associated, indicating these two signals are largely independent means this variant captures PTPN22 biology not tagged by the classic risk allele. In populations of East Asian ancestry, where R620W is nearly absent (~1% MAF), rs1217414 represents the primary accessible PTPN22 risk signal, explaining why multiple Chinese-population studies examined this SNP specifically.

The Evidence

The most compelling evidence comes from Smith et al. 2008⁴⁴ Smith et al. 2008
Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol, 2008, who genotyped 647 Type I psoriasis patients and 566 controls, then replicated in a combined dataset of 900 patients and 2,590 controls. rs1217414 demonstrated significant association (P=0.003) and the signal held when adjusted for rs2476601, confirming independence. Crucially, R620W showed no association with psoriasis at all, while rs1217414 did — a pattern that is the inverse of what is seen in rheumatoid arthritis, where R620W dominates.

In a Chinese Han cohort, Wang et al. 2015⁵⁵ Wang et al. 2015
Association of PTPN22 polymorphisms and ankylosing spondylitis susceptibility. Int J Clin Exp Pathol, 2015 found the T allele (A on plus strand) conferred substantial risk for ankylosing spondylitis (OR=2.13 for heterozygotes, OR=5.79 for homozygotes) — an additive dose-response pattern. The allele frequency in controls was ~10.5%, close to the 8% MAF in East Asian populations from dbSNP.

A large-scale Chinese Han study by Tang et al. 2016⁶⁶ Tang et al. 2016
PTPN22 polymorphisms, but not R620W, were associated with genetic susceptibility of SLE and RA in a Chinese Han population. Hum Immunol, 2016 found the same T allele (A plus strand) to be protective against both SLE (OR=0.57, padj=6×10⁻⁴; 713 cases, 672 controls) and RA (OR=0.26, padj=2×10⁻⁸; 358 cases, 564 controls). This may appear contradictory to the AS risk data, but these studies used different populations and examined different autoimmune conditions with distinct immune pathologies. The direction of effect at non-coding regulatory variants can differ by tissue context, disease type, and LD background.

In European-Americans with SLE, Namjou et al. 2013⁷⁷ Namjou et al. 2013
PTPN22 association in SLE with respect to individual ancestry and clinical sub-phenotypes. PLoS One, 2013 identified rs1217414 as an independent secondary signal alongside rs2476601, specifically in European-Americans. Neither SNP showed independent association in African-Americans or Asian-Americans.

The overall picture is moderate-evidence⁸⁸ moderate-evidence
Evidence is replicated across multiple independent studies and populations but with inconsistent direction of effect across conditions, preventing clinical-grade classification: this variant genuinely influences PTPN22-mediated immune regulation, but its directional effects differ by disease context, population background, and LD architecture.

Practical Implications

If you carry one or two copies of the A allele (GA or AA genotype), your PTPN22 regulatory activity may differ from the population average in ways that modulate autoimmune susceptibility — specifically for psoriasis and spondyloarthropathy risk. Unlike R620W, this variant does not have established associations with rheumatoid arthritis or type 1 diabetes in European populations, so the monitoring priorities differ.

The most clinically actionable finding is the psoriasis signal: if you have a personal or family history of psoriasis, early-onset skin or joint symptoms warrant dermatology evaluation. Psoriatic arthritis — the inflammatory joint disease that affects about 30% of people with psoriasis — often begins with skin disease and can progress silently before joint symptoms become prominent. PTPN22 variants have also been implicated in ankylosing spondylitis, a form of axial spondyloarthropathy; unexplained back pain with inflammatory features (morning stiffness, worsening at rest) in carriers is worth evaluating.

Interactions

The key interaction context is with rs2476601 (R620W), the primary PTPN22 variant. rs1217414 is largely independent of R620W — the two SNPs tag different haplotypes and likely different functional mechanisms. In Europeans, someone carrying both rs1217414-A and rs2476601-A faces cumulative PTPN22 dysregulation from two independent axes. In East Asian populations where R620W is rare, rs1217414 becomes the primary PTPN22 signal.

Within the psoriasis signal, rs1217414 was found to interact with rs3789604 — carrying risk alleles at both SNPs showed stronger combined association (P=0.002) than either alone, suggesting haplotype-level effects on PTPN22 regulation. rs3789604 is a nearby PTPN22 variant also in the database; together these may define a psoriasis-specific haplotype distinct from the R620W haplotype that drives RA and T1D risk.

Antithrombin — encoded by SERPINC1 on chromosome 1 — is the principal brake on coagulation. It is a serpin¹¹ serpin
serine protease inhibitor: a family of proteins that regulate coagulation, fibrinolysis, and inflammation by acting as decoy substrates for serine proteases that permanently inactivates thrombin and Factor Xa, the two enzymes most responsible for generating fibrin clot. Without functional antithrombin, coagulation runs unchecked at the slightest provocation. The Ser148Pro variant (rs121909569) in SERPINC1 substitutes proline for serine at position 148, altering the protein's conformation in a way that impairs both its heparin-binding capacity and its reactive site — a dual defect that defines type II pleiotropic effect (type II-PE) antithrombin deficiency²² type II pleiotropic effect (type II-PE) antithrombin deficiency
The most clinically severe subtype: type I reduces antigen and activity equally; type II-HBS reduces heparin binding only; type II-PE reduces both heparin-dependent and heparin-independent anticoagulant activity.

The Mechanism

Antithrombin inhibits its target proteases through a conformational mechanism called the serpin suicide substrate pathway. The reactive site loop — the region that presents itself as a decoy peptide to thrombin and Factor Xa — must be positioned correctly, and heparin binding dramatically accelerates the inhibitory reaction by bridging antithrombin to its targets. The Ser148Pro substitution introduces a proline residue into a region of the protein that connects the heparin-binding domain to the reactive site loop. Proline is conformationally rigid — it eliminates a peptide bond rotational degree of freedom that other amino acids allow — and its insertion at position 148 disrupts the transmission of the conformational change that heparin binding normally induces. The result is impaired heparin-dependent acceleration AND reduced baseline reactive site efficiency³³ impaired heparin-dependent acceleration AND reduced baseline reactive site efficiency
Pleiotropic effect classification: affects both the heparin-binding arm and the reactive site — the two mechanisms by which antithrombin inactivates thrombin and Factor Xa. Plasma antithrombin activity and antigen levels typically fall to 40–60% of normal in heterozygous carriers, leaving half the normal coagulation brake.

Homozygous antithrombin deficiency has not been reported in viable offspring, suggesting complete absence of antithrombin activity is incompatible with survival — underscoring how essential this protein is to basic hemostasis.

The Evidence

A 2024 systematic review and meta-analysis by Alnor et al.⁴⁴ 2024 systematic review and meta-analysis by Alnor et al.
39167180: Anne Alnor, Annals of Hematology — pooled data across multiple cohort studies of hereditary thrombophilia placed antithrombin deficiency at an odds ratio of 4.01 (95% CI 2.50–6.44) for venous thromboembolism — intermediate between homozygous Factor V Leiden (OR 5.58) and heterozygous Factor V Leiden (OR 2.97). This positions AT deficiency as a high-impact inherited thrombophilia, albeit with wide confidence intervals reflecting the rarity of prospective cohort data.

A review of hereditary antithrombin deficiency treatment⁵⁵ review of hereditary antithrombin deficiency treatment
Rodgers GM, Thromb Haemost 2009 synthesized earlier cohort data and estimated a ≥50% lifetime risk of VTE in confirmed AT-deficient individuals — three to seven times higher than the residual risk associated with other thrombophilias such as protein C or protein S deficiency. Antithrombin levels in heterozygous carriers typically run at 40–60% of normal — an unusually severe haploinsufficiency for a dominant variant.

The pregnancy-specific risk is particularly elevated⁶⁶ particularly elevated
Croles et al. BMJ 2017 Bayesian meta-analysis; RCT-level data are unavailable for ethical reasons, so Bayesian modeling of observational studies provides the best evidence: antithrombin deficiency carries an estimated 7.3% antepartum VTE risk (95% credible interval 1.8–15.6%) and 11.1% postpartum risk (3.7–21.0%). These absolute risks are among the highest of any inherited thrombophilia and drive the ACOG and ACCP recommendations for anticoagulant prophylaxis in affected pregnant women.

In a population-based cohort of 29,387 middle-aged Swedish adults⁷⁷ population-based cohort of 29,387 middle-aged Swedish adults
Manderstedt et al. JAHA 2022; Malmö Diet and Cancer cohort followed from 1991–2018, SERPINC1 disease-causing mutation carriers had a hazard ratio of 1.6 (95% CI 1.3–1.9) for incident VTE. This real-world unselected population estimate is lower than estimates from thrombophilia clinic cohorts (which select for symptomatic families), providing a more conservative but more generalizable risk figure.

Practical Actions

For heterozygous carriers of Ser148Pro, the clinical priorities are: documentation and disclosure (this result must be in medical records before any surgery, hospitalization, pregnancy, or hormonal therapy); thrombophilia specialist evaluation; and avoidance of high-risk provoking exposures. Routine (unprovoked) anticoagulation is not indicated for asymptomatic carriers, but high-risk situational prophylaxis during surgery, immobility, and pregnancy is strongly supported. Women considering combined hormonal contraceptives face multiplicative risk and should choose non-estrogen methods. Hematology consultation should precede any high-stakes decisions. First-degree relatives carry a 50% chance of inheriting the variant and benefit from cascade genetic testing before their first thrombotic event.

Interactions

The most clinically significant interaction is with Factor V Leiden (rs6025, F5 R506Q)⁸⁸ Factor V Leiden (rs6025, F5 R506Q)
The most common inherited thrombophilia, affecting ~5% of Europeans; compound heterozygosity with AT deficiency has been associated with much higher VTE risk than either alone. Double thrombophilia — inheriting both an antithrombin mutation and Factor V Leiden — produces additive or synergistic risk elevation. The prothrombin G20210A variant (rs1799963) represents a second compounding thrombophilic interaction. Any AT-deficient individual found to co-inherit one of these variants should have risk discussed by a hematologist as a combined clinical picture, not as two separate genetic findings.

Inside every neuron that makes dopamine or serotonin, a small enzyme called sepiapterin reductase (SPR) performs the final step in synthesising tetrahydrobiopterin¹¹ tetrahydrobiopterin
BH4 — an essential cofactor for three key enzymes in neurotransmitter production. Without sufficient BH4, the enzymes that convert tyrosine into dopamine and tryptophan into serotonin grind to a halt. The Q119X variant in SPR — a single nucleotide change that replaces glutamine at position 119 with a premature stop codon — creates a truncated, non-functional protein and is the cause of SPR deficiency (OMIM #612716), a rare but fully treatable neurological disorder.

The Mechanism

BH4 acts as a cofactor for phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryptophan hydroxylase (TPH). TH and TPH are the rate-limiting enzymes for dopamine and serotonin synthesis respectively. SPR catalyses the reduction of 6-pyruvoyltetrahydropterin to BH4 in the final step of de novo synthesis²² SPR catalyses the reduction of 6-pyruvoyltetrahydropterin to BH4 in the final step of de novo synthesis
sepiapterin reductase is an aldo-keto reductase encoded on chromosome 2p13.2. The Q119X nonsense mutation (c.355C>T, NM_003124.5) truncates the protein at codon 119, abolishing enzyme activity in skin fibroblasts. Peripheral tissues can partially compensate via alternative reductases (aldose reductase, carbonyl reductase, dihydrofolate reductase), but the brain relies predominantly on SPR — explaining why SPR deficiency is neurologically devastating while plasma phenylalanine remains normal, causing it to be invisible to standard PKU neonatal screening³³ invisible to standard PKU neonatal screening
SPR deficiency does not elevate blood phenylalanine, the marker used in universal newborn screening.

The Evidence

Bonafé et al. (2001)⁴⁴ Bonafé et al. (2001) first characterised Q119X in a consanguineous Turkish family: a 14-year-old male homozygous for the variant had psychomotor retardation, spasticity, dystonia, and severely reduced CSF levels of the dopamine metabolite homovanillic acid (HVA) and the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), with elevated biopterin. Clinical improvement followed levodopa treatment.

Friedman et al. (2012)⁵⁵ Friedman et al. (2012) described 38 patients with confirmed SPR deficiency across 11 countries. Average symptom onset was 7 months, but average time to diagnosis was 9.1 years — most patients were misdiagnosed as having cerebral palsy. The defining features were axial hypotonia, dystonia, oculogyric crises, and diurnal fluctuation (worse in the evening, better after sleep). Patients improved dramatically on levodopa/carbidopa, with further benefit from adding 5-hydroxytryptophan.

GeneReviews (Friedman & Galosi, updated 2025)⁶⁶ GeneReviews (Friedman & Galosi, updated 2025) confirms autosomal recessive inheritance and notes that early treatment — ideally within the first year of life — can reverse developmental delay and prevent permanent cognitive impairment. Levodopa is dosed at 0.1–16 mg/kg/day combined with carbidopa or benserazide; 5-HTP at 1–6 mg/kg/day.

Heterozygous carriers of Q119X are clinically asymptomatic. A population study in Malta — where the carrier frequency reaches ~4–5% due to a founder effect — found that all carrier parents showed no clinical symptoms despite carrying one defective copy of the gene. Farrugia et al. 2007⁷⁷ Farrugia et al. 2007.

Practical Actions

For homozygous individuals (TT) the situation is a medical emergency requiring specialist care. The standard treatment is levodopa/carbidopa plus 5-HTP under neurological supervision, with remarkable outcomes when started early. For heterozygous carriers (CT), current evidence does not support any supplement protocol — carriers are phenotypically normal. The main practical value of knowing carrier status is for reproductive planning: two CT carriers have a 25% chance of an affected (TT) child per pregnancy.

Interactions

SPR deficiency shares its pathway with GTP cyclohydrolase I deficiency (GCH1 mutations, the dominant form of DOPA-responsive dystonia) and other BH4 biosynthesis disorders. All these conditions converge on the same downstream deficiency of dopamine and serotonin. SPR also interacts with the nitric oxide synthase pathway — BH4 is a cofactor for NOS enzymes, so severe SPR deficiency secondarily impairs nitric oxide production, contributing to autonomic dysfunction seen in roughly half of patients.

HLA-C¹¹ HLA-C
Human leukocyte antigen C is a class I MHC gene encoding a cell-surface protein that presents intracellular peptides to CD8+ T cells, allowing the immune system to distinguish self from non-self and from infected or aberrant cells sits at the heart of the psoriasis story. The rs12191877 SNP is a tag variant²² tag variant
A tag SNP doesn't cause disease itself but travels in tight linkage disequilibrium with the functional allele due to shared inheritance, serving as a reliable marker for it for the HLA-C*06:02 allele (historically called HLA-Cw6), the most strongly replicated genetic risk factor for psoriasis ever identified. Unusually for a common disease, this single allele accounts for roughly 35-50% of the genetic contribution³³ 35-50% of the genetic contribution
PSORS1 locus on chromosome 6p21.3 explains the majority of genetic variance in psoriasis; HLA-C*06:02 is the primary susceptibility variant within PSORS1 to disease risk—far exceeding the contribution of any other locus.

The Mechanism

Psoriasis is now understood to be a primary autoimmune disease directed against melanocytes⁴⁴ autoimmune disease directed against melanocytes
Melanocytes are the pigment-producing cells of the epidermis; in psoriasis, CD8+ T cells attack them through HLA-C*06:02-restricted antigen presentation—not merely an inflammatory skin condition. HLA-C*06:02 presents the melanocyte-derived peptide ADAMTSL5⁵⁵ ADAMTSL5
ADAMTS-like protein 5, a secreted glycoprotein expressed specifically in melanocytes; when processed and presented by HLA-C*06:02, it triggers a CD8+ T cell response that drives psoriatic inflammation to CD8+ T cells in the epidermis, triggering the signature IL-17A-driven inflammatory cascade that leads to keratinocyte hyperproliferation and the characteristic scaly plaques. The ERAP1⁶⁶ ERAP1
Endoplasmic reticulum aminopeptidase 1; trims peptides before loading onto HLA class I molecules. ERAP1 variants affect how much ADAMTSL5 peptide is generated for HLA-C*06:02 presentation aminopeptidase controls the supply of this autoantigenic peptide, explaining the well-documented epistatic interaction between HLA-C and ERAP1 variants in psoriasis GWAS.

The gene-dose effect is biologically meaningful. Heterozygous carriers express HLA-C*06:02 on fewer antigen-presenting cells than homozygotes, generating a weaker and less sustained T-cell response. This produces the graded risk seen clinically: homozygotes have substantially higher lifetime risk and earlier onset than heterozygotes.

The Evidence

Feng et al.⁷⁷ Feng et al.
Feng BJ et al. Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet. 2009;5(8):e1000606 performed a large GWAS identifying rs12191877 as the most significant single SNP (OR 2.92, p=3×10⁻⁵³), but demonstrated that imputed HLA-Cw*0602 dosage showed even stronger association (OR 3.85, p=8×10⁻⁶¹), confirming rs12191877 as a tag for the true causal allele rather than the functional variant itself.

Strange et al.⁸⁸ Strange et al.
Strange A et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985-990 extended this with 2,622 cases and 5,667 controls from the UK and Ireland, identifying the related tag rs10484554 at OR 4.66 (p=4×10⁻²¹⁴)—among the strongest single-variant associations documented in common disease GWAS. The same study demonstrated the epistatic interaction: ERAP1 variants only influenced psoriasis risk in HLA-C risk allele carriers⁹⁹ ERAP1 variants only influenced psoriasis risk in HLA-C risk allele carriers
Stratified analysis showed ERAP1 OR 1.43 in HLA-C risk carriers vs. no effect in non-carriers, combined p=6.95×10⁻⁶.

The clinical phenotype data are striking. Chen and Tsai¹⁰¹⁰ Chen and Tsai
Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854-862 reviewed decades of studies showing that HLA-Cw6 (HLA-C*06:02) consistently associates with type I early-onset psoriasis (peak ages 18-22), guttate morphology, Koebner phenomenon, positive family history, and reduced nail involvement compared to HLA-Cw6-negative disease. In populations studied for guttate psoriasis specifically, HLA-Cw6 prevalence reaches 73-100% of affected individuals.

The streptococcal trigger connection is also HLA-dependent. Mallbris et al.¹¹¹¹ Mallbris et al.
Mallbris L et al. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis. BMC Dermatol. 2009;9:5 found that HLA-Cw*0602-positive patients showed twice the rate of positive streptococcal throat cultures at disease onset (OR 3.5 for guttate, OR 2.3 for plaque psoriasis), consistent with molecular mimicry between streptococcal and skin antigens.

Practical Actions

The most actionable implication of HLA-C*06:02 status is biologic selection. Dand et al.¹²¹² Dand et al.
Dand N et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120-2130 analyzed 1,326 patients receiving adalimumab or ustekinumab and found that HLA-C*06:02-negative patients responded significantly better to adalimumab than ustekinumab at all timepoints (OR 2.95 at 6 months; OR 5.98 in those with concomitant psoriatic arthritis). HLA-C*06:02-positive patients without psoriatic arthritis showed poorer adalimumab response at 12 months. For ustekinumab specifically, Van Vugt et al.¹³¹³ Van Vugt et al.
Van Vugt LJ et al. Association of HLA-C*06:02 status with differential response to ustekinumab. JAMA Dermatol. 2019;155(6):708-715 confirmed in a meta-analysis of 8 studies (1,048 patients) that HLA-C*06:02-positive patients achieve 89% vs. 62% PASI75 response at 6 months. Secukinumab (anti-IL-17A) efficacy is high regardless of HLA-C*06:02 status, making it a reasonable choice for either genotype.

For TT homozygotes in particular, the elevated lifetime risk warrants dermatology awareness, prompt evaluation when skin changes appear, and advance discussion of treatment options before disease becomes severe.

Interactions

The documented ERAP1 epistasis is the most important gene-gene interaction here. ERAP1 risk haplotypes (particularly Hap2) compound the psoriasis risk in HLA-C*06:02 carriers by generating more autoantigenic ADAMTSL5 peptide for HLA-C*06:02 presentation. ERAP1 protective haplotypes (Hap10) reduce melanocyte immunogenicity even in HLA-C*06:02 carriers. This interaction explains why not all HLA-C*06:02 carriers develop psoriasis. At the population level, the GWAS-defined epistasis is confined largely to disease onset between ages 10-20, suggesting genetic heterogeneity within childhood-onset psoriasis. rs2187668 (HLA-DQA1 — DQ2.5 tag) shares the same chromosomal region on 6p21, reflecting the complex multi-locus HLA architecture governing multiple immune-mediated diseases at this locus.